EA202193111A1 - Композиции и способы для лечения рака - Google Patents

Композиции и способы для лечения рака

Info

Publication number
EA202193111A1
EA202193111A1 EA202193111A EA202193111A EA202193111A1 EA 202193111 A1 EA202193111 A1 EA 202193111A1 EA 202193111 A EA202193111 A EA 202193111A EA 202193111 A EA202193111 A EA 202193111A EA 202193111 A1 EA202193111 A1 EA 202193111A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
cancer
subject
compositions
treatment
Prior art date
Application number
EA202193111A
Other languages
English (en)
Inventor
Стивен Хоффман
Original Assignee
Тайм, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тайм, Инк. filed Critical Тайм, Инк.
Publication of EA202193111A1 publication Critical patent/EA202193111A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Изобретение представляет способы лечения рака. Настоящее изобретение относится к способам лечения рака путем увеличения окислительного стресса в раковой клетке. В частности, настоящее изобретение относится к способам лечения рака у субъекта, включающим снижение запасов гликогена у субъекта и введение субъекту эффективного количества производного тирозина.
EA202193111A 2019-05-14 2020-05-14 Композиции и способы для лечения рака EA202193111A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847570P 2019-05-14 2019-05-14
PCT/US2020/032847 WO2020232227A1 (en) 2019-05-14 2020-05-14 Compositions and methods for treating cancer

Publications (1)

Publication Number Publication Date
EA202193111A1 true EA202193111A1 (ru) 2022-02-10

Family

ID=73245256

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193111A EA202193111A1 (ru) 2019-05-14 2020-05-14 Композиции и способы для лечения рака

Country Status (12)

Country Link
US (1) US11534420B2 (ru)
EP (1) EP3968785A4 (ru)
JP (1) JP2022532210A (ru)
KR (1) KR20220098682A (ru)
CN (1) CN114173578A (ru)
AU (1) AU2020276605A1 (ru)
BR (1) BR112021022784A2 (ru)
CA (1) CA3140042A1 (ru)
EA (1) EA202193111A1 (ru)
IL (1) IL287982A (ru)
MX (1) MX2021013901A (ru)
WO (1) WO2020232227A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220098682A (ko) 2019-05-14 2022-07-12 타임, 인크. 암을 치료하기 위한 조성물 및 방법
EP4045027A1 (en) * 2019-10-15 2022-08-24 Tyme, Inc. Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
CN115515575A (zh) * 2020-01-17 2022-12-23 迪美公司 用于调节癌症的酪氨酸衍生物
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
WO2022120039A2 (en) * 2020-12-02 2022-06-09 Steven Hoffman Compositions and methods for modulating cancer in non-human mammals

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029547A (en) 1974-07-01 1977-06-14 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Biologically active substance, bestatin, and production thereof
US4117161A (en) 1977-05-16 1978-09-26 Jose Pozuelo Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine
US4165382A (en) 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4389415A (en) 1978-01-24 1983-06-21 Merck & Co., Inc. Method of treating hypertension
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
GB8706313D0 (en) 1987-03-17 1987-04-23 Health Lab Service Board Treatment & prevention of viral infections
DE8907335U1 (ru) 1989-06-15 1990-10-18 Espe Stiftung & Co Produktions- Und Vertriebs Kg, 8031 Seefeld, De
WO1991000270A1 (en) 1989-06-30 1991-01-10 Chemical Works Of Gedeon Richter Ltd. Process for the resolution of threo-3-[(2-aminophenyl)-thio]-2-hydroxy-3-(4-methoxy-phenyl)propionic acid
US5029760A (en) 1989-10-26 1991-07-09 Gamblin Rodger L Centrifugal grinding and mixing apparatus
JPH03161442A (ja) 1989-11-21 1991-07-11 Chiyouseidou Seiyaku Kk コール酸又はそのナトリウム塩からなる脳代謝改善剤
US5225435A (en) 1990-05-18 1993-07-06 Yale University Soluble melanin
US5310539A (en) 1991-04-15 1994-05-10 Board Of Regents, The University Of Texas System Melanin-based agents for image enhancement
CA2139757C (en) 1992-07-08 2009-04-14 Gunther Maierhofer Liposomes, method of preparing the same and use thereof in the preparation of drugs
DE4342174C1 (de) 1993-12-10 1995-05-11 Lohmann Therapie Syst Lts Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
JP2000507938A (ja) 1996-03-22 2000-06-27 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 結腸直腸の化学的保護のためのウルソデオキシコール酸化合物及びｎｓａｉｄの組合せ
US5733926A (en) 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
IT1291633B1 (it) 1997-04-22 1999-01-11 Pharmaconsult S A S Uso dell'alfa-metil-p-tirosina per inibire la produzione di melanina nei melanociti dell'iride
US5929055A (en) 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
US5952374A (en) 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
AU775289B2 (en) 1998-08-21 2004-07-29 Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
DE19906977C1 (de) 1999-02-19 2000-06-15 Lohmann Therapie Syst Lts Desoxypeganin-TTS und seine Verwendung
JP2002196006A (ja) 2000-12-27 2002-07-10 Olympus Optical Co Ltd 自動分析装置
SK288546B6 (sk) 2001-02-19 2018-03-05 Novartis Ag 40-O-(2-hydroxyetyl)rapamycín v kombinácii s exemestánom alebo letrozolom na použitie pri liečení nádoru prsníka
WO2002098403A1 (en) 2001-06-01 2002-12-12 Georgetown University Steroid hormone and non-steroidal anti-inflammatory drug combinations for inducing tumor cell apoptosis
JP4609875B2 (ja) 2001-07-31 2011-01-12 有限会社大長企画 健康食品
US7338971B2 (en) 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
JP4091557B2 (ja) 2003-03-18 2008-05-28 株式会社マンダム 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品
CA2554246A1 (en) 2004-01-29 2005-08-11 Baxter International Inc. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
EP1718145A4 (en) 2004-02-02 2012-03-07 Biosight Ltd CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS
EP1674081A1 (de) 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
WO2006099685A1 (en) 2005-03-24 2006-09-28 Medical Therapies Limited Method for the prophylaxis or treatment of carcinomas
JP2008534505A (ja) 2005-03-25 2008-08-28 メルク エンド カムパニー インコーポレーテッド テストステロンサプリメントおよび５アルファ−レダクターゼインヒビターによる男性の治療方法
US20060223877A1 (en) 2005-03-31 2006-10-05 Zemlan Frank P Methods of treatment utilizing certain melatonin derivatives
CN102225046A (zh) 2005-08-05 2011-10-26 努沃研究公司 透皮释药剂型
US8039511B2 (en) 2005-11-15 2011-10-18 Wuxi Jc Pharmaceutical Technology Co., Ltd. Use of isothiocyanates compounds in treating prostatic diseases and skin cancer
KR101653182B1 (ko) 2006-04-19 2016-09-01 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 세포 영상화 및 치료를 위한 조성물 및 방법
EP1884243A1 (en) 2006-05-02 2008-02-06 Charité - Universitätsmedizin Berlin Use of an antipsychotic drug for the treatment of ALS-associated cachexia
CN101138634A (zh) 2006-09-07 2008-03-12 于保法 用于***的组合物
WO2008062475A2 (en) 2006-10-26 2008-05-29 Cadila Healthcare Limited Pharmaceutical compositions of ursodiol
CA2727866A1 (en) 2008-06-13 2009-12-17 Wisconsin Alumni Research Foundation Novel peptide adjuvant for influenza vaccination
EP2208497A1 (en) 2009-01-15 2010-07-21 Charité-Universitätsmedizin Berlin (Charité) Use of Ursodeoxycholic acid (UDCA) for enhancing the general health condition of a tumor patient
US20170029892A1 (en) 2009-05-29 2017-02-02 Jay L. Lombard Methods and compositions for the treatment of post-traumatic stress disorder
WO2011011716A1 (en) 2009-07-23 2011-01-27 The Trustees Of Princeton University Inhibitors of mtor kinase as anti-viral agents
CN102753162A (zh) * 2009-10-22 2012-10-24 南加利福尼亚大学 增加癌症治疗的效力和降低副作用的方法和营养配方
WO2011053835A1 (en) 2009-10-30 2011-05-05 Aton Pharma, Inc. Stereoselective synthesis of metyrosine
KR101131675B1 (ko) 2010-01-28 2012-03-28 조선대학교산학협력단 우루소데옥시콜린산을 유효성분으로 함유하는 위암의 예방 또는 치료용 조성물
AU2011241175A1 (en) 2010-04-16 2012-11-29 Davos Life Science Pte. Ltd. Synergistic interaction of at least one Vitamin E component and tyrosinase inhibitors for dermatological applications
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US9949923B2 (en) 2011-03-15 2018-04-24 Optinose As Nasal delivery
PL220308B1 (pl) 2011-06-03 2015-10-30 Kobel Buys Krystyna Zastosowanie klenbuterolu do leczenia objawów autyzmu dziecięcego oraz klenbuterol do zastosowania w leczeniu objawów autyzmu dziecięcego
CN102397550B (zh) 2011-08-30 2013-05-08 广东医学院 一组由阿司匹林与***组成的防治骨质疏松症的药物组合物
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
WO2013096870A1 (en) 2011-12-22 2013-06-27 Knopp Neurosciences Inc Compositions and methods for treating amyotrophic lateral sclerosis
CN104039327B (zh) 2012-01-06 2017-02-15 大熊制药株式会社 含有牛磺熊去氧胆酸的组合物
CA2862689C (en) 2012-01-17 2020-03-10 Tyme, Inc. .alpha.-methyl-dl-tyrosine, compositions, kits, combinations and use thereof for the treatment of cancer or for reducing cell proliferation
US10272068B2 (en) 2012-01-17 2019-04-30 Tyme, Inc. Pharmaceutical compositions and methods
US10646552B2 (en) 2012-01-17 2020-05-12 Tyme, Inc. Pharmaceutical compositions and methods
US20130183263A1 (en) 2012-01-17 2013-07-18 Steven Hoffman Pharmaceutical compositions and methods
US8481498B1 (en) 2012-01-17 2013-07-09 Steven Hoffman Pharmaceutical compositions and methods
US20210386832A1 (en) 2012-01-17 2021-12-16 Tyme, Inc. Pharmaceutical Compositions And Methods
US20150072967A1 (en) 2012-03-20 2015-03-12 Metselex, Inc. Tauroursodeoxycholic acid attentuates or abolishes formation and deposition of amyloid-b peptide
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
GB201216800D0 (en) 2012-09-20 2012-11-07 Immodulon Therapeutics Ltd Novel use
US11419922B2 (en) 2012-11-16 2022-08-23 Eric Finzi Treatment of post-traumatic stress disorder using botulinum toxin A
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
KR20160030162A (ko) 2013-07-11 2016-03-16 가부시키가이샤 폴라 파마 사용시 거품상을 나타내는 외용 조성물
US20150111878A1 (en) 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US20170080093A1 (en) 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
US9724657B2 (en) 2013-10-22 2017-08-08 Tyme, Inc. High-speed centrifugal mixing devices and methods of use
US9326962B2 (en) 2013-10-22 2016-05-03 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
CN103919787A (zh) 2014-04-17 2014-07-16 厦门大学 牛磺熊脱氧胆酸及其可接受的盐的制药用途
EP3169707B1 (en) 2014-07-11 2020-12-02 The Regents of the University of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
CN106794188B (zh) 2014-09-28 2022-12-02 华辉安健（北京）生物科技有限公司 聚合胆汁酸衍生物抑制乙型肝炎病毒和丁型肝炎病毒和ntcp运输
GB201419257D0 (en) 2014-10-29 2014-12-10 Jagotec Ag Pharmaceutical compositions
WO2016105530A1 (en) 2014-12-23 2016-06-30 Steven Hoffman Transdermal formulations
US9687528B2 (en) 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations
CN106031731A (zh) 2015-03-18 2016-10-19 中国医学科学院基础医学研究所 牛磺熊去氧胆酸的新用途
CA2982442A1 (en) 2015-04-14 2016-10-20 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US20170181993A1 (en) 2015-12-28 2017-06-29 Steven Hoffman Methods of Treating Amyotrophic Lateral Sclerosis and Symptoms
BR112018068027A2 (pt) * 2016-03-15 2019-01-08 Tyme Inc método para tratar câncer em um paciente e composição farmacêutica
KR102466886B1 (ko) 2016-05-18 2022-11-14 타임, 인크. 암의 치료에서의 디히드로테스토스테론 및 디히드로테스토스테론 유도체 및 프로모터
BR112019004540A2 (pt) 2016-09-12 2019-05-28 Hoffman Steven método para tratar demência em um paciente, composição farmacêutica, método para tratar demência em um paciente, método para reduzir a probabilidade de desenvolver demência em um paciente, composição para uso no tratamento de demência em um paciente, composição e composição para uso na redução da probabilidade de desenvolver demência em um paciente submetido a uma terapia longa de um fármaco não-esteroide anti-inflamatório ou aspirina
JP2019537608A (ja) 2016-11-15 2019-12-26 タイム，インコーポレーテッド 癌の処置のための医薬組成物および方法
CA3045110A1 (en) 2016-11-30 2018-06-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
EA201992515A1 (ru) 2017-04-21 2020-04-09 Стивен Хоффман Композиции и способы для лечения ретинопатии
US20200246449A1 (en) 2017-05-03 2020-08-06 Nanobio Corporation Intravenous immunoglobulin compositions specific for respiratory syncytial virus and methods of making and using the same
JP7170722B2 (ja) 2017-07-19 2022-11-14 ホフマン・テクノロジーズ・エルエルシー ストレス関連障害を治療するための組成物
CA3075091A1 (en) 2017-09-15 2019-03-21 Tyme, Inc. Transdermal formulations
CA3083343C (en) 2017-12-28 2022-04-26 J-Pharma Co., Ltd. O-(5-amino-2-phenylbenzoxazol-7-yl)methyl-3,5-dichloro-l-tyrosine for use in treating cancer
JP2021530482A (ja) 2018-07-09 2021-11-11 タイム，インコーポレーテッド 腫瘍を減少させる製剤およびその使用方法
US20210275467A1 (en) 2018-07-09 2021-09-09 Tyme, Inc Tumor reduction formulations and methods of use thereof
CN112822997A (zh) 2018-07-19 2021-05-18 亚莫制药有限公司 用于治疗孤独症的组合物和方法
US20200163952A1 (en) 2018-11-26 2020-05-28 Steven Hoffman Compositions and methods for treating nerve agent exposure
CN110563602A (zh) 2018-12-26 2019-12-13 南宁多灵生物科技有限公司 迷迭香酸衍生物及其制备方法和应用
JP2022519541A (ja) 2019-02-01 2022-03-24 ホフマン・テクノロジーズ・エルエルシー 不安関連障害を処置するための組成物および方法
US20200282014A1 (en) 2019-03-05 2020-09-10 Hoffman Technologies Llc Percutaneous anti-microbiota formulations
KR20220092452A (ko) 2019-03-22 2022-07-01 타임, 인크. D-메티로신 조성물 및 그의 제조 방법
JP2022529189A (ja) 2019-04-19 2022-06-17 ホフマン・テクノロジーズ・エルエルシー 持続放出製剤
KR20220098682A (ko) 2019-05-14 2022-07-12 타임, 인크. 암을 치료하기 위한 조성물 및 방법
WO2021015437A1 (ko) 2019-07-22 2021-01-28 고려대학교 산학협력단 활성산소 생성억제제 및 활성산소 소거제 복합물을 유효성분으로 포함하는 바이러스 감염 질환의 예방, 치료, 또는 개선용 조성물
EP4045027A1 (en) 2019-10-15 2022-08-24 Tyme, Inc. Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
CN114945374A (zh) 2019-12-09 2022-08-26 迪美公司 药物组合物和方法
CN115515575A (zh) 2020-01-17 2022-12-23 迪美公司 用于调节癌症的酪氨酸衍生物
US20230165940A1 (en) 2020-04-08 2023-06-01 Hoffman Technologies Llc Methods of treating conditions characterized by insulin deficiency in animals
WO2021231931A1 (en) 2020-05-14 2021-11-18 Tyme, Inc. Methods of treating sars-cov-2 infections
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
US20220002227A1 (en) 2020-07-01 2022-01-06 Tyme, Inc. Crystalline forms of metyrosine

Also Published As

Publication number Publication date
AU2020276605A1 (en) 2022-01-20
MX2021013901A (es) 2022-04-12
US11534420B2 (en) 2022-12-27
BR112021022784A2 (pt) 2022-03-22
EP3968785A4 (en) 2023-01-11
CN114173578A (zh) 2022-03-11
US20200360328A1 (en) 2020-11-19
KR20220098682A (ko) 2022-07-12
WO2020232227A1 (en) 2020-11-19
EP3968785A1 (en) 2022-03-23
CA3140042A1 (en) 2020-11-19
JP2022532210A (ja) 2022-07-13
IL287982A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
EA202193111A1 (ru) Композиции и способы для лечения рака
EA202092590A1 (ru) Пиридазиноны в качестве ингибиторов parp7
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
EA202190630A1 (ru) Способы комбинированной терапии
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
EA201890571A1 (ru) Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9)
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201500996A1 (ru) Терапевтические применения эмпаглифлозина
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
MX2022000027A (es) Extracto de ca?amo para tratamiento del dolor, cancer y epilepsia en animales.
MX2022009596A (es) Anticuerpos anti-ror1 y composiciones.
JOP20190241B1 (ar) مستحضرات رذاذ إبينيفرين
EA202091205A1 (ru) Композиции для терапии гипергликемии и сопутствующих состояний
EA202092824A1 (ru) Комбинированная терапия
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA202090705A1 (ru) Способы и композиции, предназначенные для лечения хронических заболеваний легких
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
EA202092691A1 (ru) Соединения для устранения боли, композиции, содержащие их, и способы их применения
EA202190798A1 (ru) Ротамерные изомеры 4-алкил-5-гетероарил-3h-1,2-дитиол-3-тионов
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения